Enzychem Lifesciences Corporation (KOSDAQ:183490)
South Korea flag South Korea · Delayed Price · Currency is KRW
990.00
-27.00 (-2.65%)
Mar 25, 2026, 7:48 AM KST

Enzychem Lifesciences Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
61,86067,75177,37876,03926,63822,975
Revenue Growth
-18.52%-12.44%1.76%185.46%15.94%-11.01%
Gross Profit
2,1313,3834,3104,3482,416286.72
Operating Income
-18,409-18,270-16,376-14,733-14,662-20,754
Net Income
-18,121-18,132-22,107-9,326-24,934-26,923
Earnings Per Share
-233.54-234.50-270.00-110.00-316.34-533.20
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
104,00792,821117,075137,350192,85694,587
Total Debt
5,7014,8394,8805,65737,77951,977
Net Cash (Debt)
98,30787,982112,195131,693155,07742,609
Net Cash Growth
-6.96%-21.58%-14.81%-15.08%263.95%-10.18%
Net Cash Per Share
1267.001137.891370.301550.621967.48843.86

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-10,610-11,012-573.93-10,258-14,320-18,589
Capital Expenditures
-548.42-762.68-323.82-2,248-7,957-5,818
Free Cash Flow
-11,159-11,775-897.74-12,506-22,277-24,407
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
3.45%4.99%5.57%5.72%9.07%1.25%
Operating Margin
-29.76%-26.97%-21.16%-19.38%-55.04%-90.33%
Pretax Margin
-29.57%-26.92%-28.54%-12.99%-96.03%-128.42%
Profit Margin
-29.29%-26.76%-28.57%-12.26%-93.60%-117.18%
FCF Margin
-18.04%-17.38%-1.16%-16.45%-83.63%-106.23%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
1.241.751.472.035.2419.91